FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease

Prior treatment

• Indication for or previous coronary artery bypass grafting
• Complicated IRA treatment, e.g. extravasation, permanent no re-flow after IRA treatment (TIMI flow 0-1) and inability to implant a stent
• Gastrointestinal or genitourinary bleeding within the prior 3 months.
• Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment.
• Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.

Other illness

• Left main disease (stenosis \> 50%)
• Known severe cardiac valve dysfunction that will require surgery or TAVI in the follow-up period.

Other

• Chronic total occlusion of a non-IRA
• Uncertain culprit lesion
• Killip class III or IV during the completion of culprit lesion treatment.
• Life expectancy of \< 1 year.
• Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor or Heparin.
• Pregnancy

• Patients aged between 18-85 years presenting with non-STEMI according to current guidelines, who will be treated with PCI of the culprit and have at least one stenosis of \>50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator.
• Non-IRA stenosis amenable for PCI treatment (operator's decision)
• Signed informed consent